sorafenib has been researched along with deferasirox in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 832 | 136 | 572 |
| Protein | Taxonomy | sorafenib (IC50) | deferasirox (IC50) |
|---|---|---|---|
| Lysine-specific demethylase 6B | Homo sapiens (human) | 3.95 | |
| Lysine-specific demethylase 4A | Homo sapiens (human) | 3.77 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Akita, T; Jomen, W; Kohgo, Y; Ohtake, T; Osawa, Y; Suto, D; Yagi, H | 1 |
1 review(s) available for sorafenib and deferasirox
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorafenib and deferasirox
| Article | Year |
|---|---|
Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Line, Tumor; Deferasirox; Humans; Iron Chelating Agents; Liver Neoplasms; NF-kappa B; Sorafenib | 2022 |